The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future
Open accessAbstract
Plant-based psychedelics, such as psilocybin, have an ancient history of medicinal use. After the first English language report on LSD in 1950, psychedelics enjoyed a short-lived relationship with psychology and psychiatry. Used most notably as aids to psychotherapy for the treatment of mood disorders and alcohol dependence, drugs such as LSD showed initial therapeutic promise before prohibitive legislature in the mid-1960s effectively ended all major psychedelic research programs. Since the early 1990s, there has been a steady revival of human psychedelic research: last year saw reports on the first modern brain imaging study with LSD and three separate clinical trials of psilocybin for depressive symptoms. In this circumspective piece, RLC-H and GMG share their opinions on the promises and pitfalls of renewed psychedelic research, with a focus on the development of psilocybin as a treatment for depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Classic psychedelics, such as synthetic LSD and psilocybin, which is found in certain mushrooms, have shown promise as aids in psychotherapy e.g., for mood disorders and substance dependence [1, 5, 33].”
From Mindfulness meditation and psychedelics: potential synergies and commonalities (2023) · cites this paper as [1]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In contrast, classical psychedelics are not generally considered to be addictive (Carhart-Harris and Goodwin, 2017;Nichols et al., 2017) as animals will not readily self-administer these compounds (Fantegrossi et al., 2008).”
From Psychedelics and Neural Plasticity: Therapeutic Implications (2022) · cites this paper as Carhart-Harris and Goodwin, 2017
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 6×
“…clinical development of psychedelics, RLC-H sees it as a potentially exploitable component—especially as it has been shown to be predictive of long-term clinical outcomes (eg, in Johnson et al, 2014; Bogenschutz et al, 2015; Griffiths et al, 2016; Ross et al, 2016; Carhart-Harris et al, 2016a,b).”
BackgroundInfluentialRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 2×
“…et al, 2004, 2006; Vollenweider et al, 1997), psychology (Carhart-Harris et al, 2015, 2016c; Carter et al, 2007; Gouzoulis-Mayfrank et al, 2005; Griffiths et al, 2006; MacLean et al, 2011; Schmid et al, 2015), and psychopharmacology studies with psychedelics (Kometer et al, 2012; Preller et…”
BackgroundCarhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Self-citationPilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172
Self-citationPsilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151 · cited 3×
“…clinical development of psychedelics, RLC-H sees it as a potentially exploitable component—especially as it has been shown to be predictive of long-term clinical outcomes (eg, in Johnson et al, 2014; Bogenschutz et al, 2015; Griffiths et al, 2016; Ross et al, 2016; Carhart-Harris et al, 2016a,b).”
BackgroundPsilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018
5-HT and mechanisms of defence
Deakin, J. F. W., & Graeff, F. G. (1991) · Journal of Psychopharmacology · doi:10.1177/026988119100500414 · Cited by 1,011
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970
Self-citationPilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · cited 2×
“…clinical development of psychedelics, RLC-H sees it as a potentially exploitable component—especially as it has been shown to be predictive of long-term clinical outcomes (eg, in Johnson et al, 2014; Bogenschutz et al, 2015; Griffiths et al, 2016; Ross et al, 2016; Carhart-Harris et al, 2016a,b).”
BackgroundMacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895
Neural correlates of the LSD experience revealed by multimodal neuroimaging
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., Tagliazucchi, E., Schenberg, E. E., Nest, T., Orban, C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518377113 · Cited by 859
Self-citationSafety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1110 · Cited by 789
(2001) · PubMed · Cited by 780
Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000113 · Cited by 750
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Krebs, T. S., & Johansen, P.-Ø. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439253 · Cited by 583
Broadband Cortical Desynchronization Underlies the Human Psychedelic State
Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R., Brookes, M. J., Williams, T. M., Errtizoe, D., Sessa, B., Papadopoulos, A., Bolstridge, M., Singh, K. D., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.2063-13.2013 · Cited by 499
Self-citationOsório, F. D. L., Sanches, R. F., Macedo, L. R., dos Santos, R. G., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A., & Hallak, J. E. (2015) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2014-1496 · Cited by 488
Hartogsohn, I. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116677852 · Cited by 483
Sanches, R. F., de Lima Osório, F., dos Santos, R. G., Macedo, L. R. H., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000436 · Cited by 466
Stuck in a rut: rethinking depression and its treatment
Holtzheimer, P. E., & Mayberg, H. S. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2010.10.004 · Cited by 456
Palhano-Fontes, F., Andrade, K. C., Tofoli, L. F., Santos, A. C., Crippa, J. A. S., Hallak, J. E. C., Ribeiro, S., & de Araujo, D. B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118143 · Cited by 454
Vollenweider, F. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00246-1 · Cited by 444
Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects
Schmid, Y., Enzler, F., Gasser, P., Grouzmann, E., Preller, K. H., Vollenweider, F. X., Brenneisen, R., Müller, F., Borgwardt, S., & Liechti, M. E. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.11.015 · Cited by 427
What has serotonin to do with depression?
Cowen, P. J., & Browning, M. D. (2015) · World Psychiatry · doi:10.1002/wps.20229 · Cited by 410
Hendricks, P. S., Thorne, C. B., Clark, C. B., Coombs, D. W., & Johnson, M. W. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565653 · Cited by 410
Preller, K. H., Herdener, M., Pokorny, T., Planzer, A., Kraehenmann, R., Stämpfli, P., Liechti, M. E., Seifritz, E., & Vollenweider, F. X. (2017) · Current Biology · doi:10.1016/j.cub.2016.12.030 · Cited by 402
McCabe, C., Mishor, Z., Cowen, P. J., & Harmer, C. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.11.001 · Cited by 365
“The Electric Kool-Aid Acid Test”
Wolfe, T. M. (2012) · Routledge eBooks · doi:10.4324/9780203086612-27 · Cited by 344
Management of depression for people with cancer (SMaRT oncology 1): a randomised trial
Strong, V., Waters, R., Hibberd, C. J., Murray, G. D., Wall, L. R., Walker, J., McHugh, G. S., Walker, A., & Sharpe, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60991-5 · Cited by 324
LSD enhances suggestibility in healthy volunteers
Carhart-Harris, R. L., Kaelen, M., Whalley, M. G., Bolstridge, M., Feilding, A., & Nutt, D. J. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3714-z · Cited by 320
Self-citationBouso, J. C., González, D., Fondevila, S., Cutchet, M., Fernández, X., Ribeiro Barbosa, P. C., Alcázar-Córcoles, M. Á., Araújo, W. S., Barbanoj, M. J., Fábregas, J. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042421 · Cited by 313
Realms of the Human Unconscious: Observations from LSD Research
McLaughlin, S. C., & Grof, S. (1976) · Journal for the Scientific Study of Religion · doi:10.2307/1385643 · Cited by 311
Kometer, M., Schmidt, A., Bachmann, R., Studerus, E., Seifritz, E., & Vollenweider, F. X. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.04.005 · Cited by 298
Paradoxical trafficking and regulation of 5-HT2A receptors by agonists and antagonists
Gray, J. A. B., & Roth, B. L. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00623-2 · Cited by 296
The paradoxical psychological effects of lysergic acid diethylamide LSD
Carhart-Harris, R. L., Kaelen, M., Bolstridge, M., Williams, T. M., Williams, L. T., Underwood, R., Feilding, A., & Nutt, D. J. (2016) · Psychological Medicine · doi:10.1017/s0033291715002901 · Cited by 293
Self-citationDose-Response Study of N,N-Dimethyltryptamine in Humans
Strassman, R. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020009001 · Cited by 291
LYSERGIC ACID DIETHYLAMIDE: SIDE EFFECTS AND COMPLICATIONS
COHEN, S. (1960) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196001000-00005 · Cited by 287
Psilocybin, ein psychotroper Wirkstoff aus dem mexikanischen RauschpilzPsilocybe mexicana Heim
Hofmann, A., Heim, R., Brack, A., & Kobel, H. (1958) · Experientia · doi:10.1007/bf02159243 · Cited by 282
Psychedelic Drugs Reconsidered
Seelye, E. E. (1980) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.1980.34.4.593 · Cited by 257
Storming Heaven: LSD and the American Dream
Stevens, J. (1987) · DigitalGeorgetown (Georgetown University Library) · Cited by 241
Increased frontal and paralimbic activation following ayahuasca, the pan-amazonian inebriant
Riba, J., Romero, S., Grasa, E., Mena, E., Carrió, I., & Barbanoj, M. J. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0358-7 · Cited by 241
Psychedelic Drugs Reconsidered
Grinspoon, L., & Bakalar, J. B. (1979) · Medical Entomology and Zoology · Cited by 239
Carhart-Harris, R. L., Leech, R., Williams, T. M., Erritzoe, D., Abbasi, N., Bargiotas, T., Hobden, P., Sharp, D. J., Evans, J., Feilding, A., et al. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.103309 · Cited by 237
Self-citationSharpe, M., Strong, V., Allen, K., Rush, R., Postma, K., Tulloh, A., Maguire, P., House, A. O., Ramirez, A., & Cull, A. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601578 · Cited by 232
Thienpont, L., Verhofstadt, M., Van Loon, T., Distelmans, W., Audenaert, K., & De Deyn, P. P. (2015) · BMJ Open · doi:10.1136/bmjopen-2014-007454 · Cited by 231
van Amsterdam, J., Nutt, D., Phillips, L., & van den Brink, W. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581980 · Cited by 229 · cited 1×
“…alarmist campaigning that so negatively affected perceptions of psychedelics after the 1960s, subjective (Carhart-Harris and Nutt, 2010, 2013; van Amsterdam et al, 2015), naturalistic/ observational (Bouso et al, 2012), and population-based data (Hendricks et al, 2015) indicate a positive…”
BackgroundHarmer, C. J., & Cowen, P. J. (2013) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2012.0407 · Cited by 197
Psychedelics in the treatment of unipolar mood disorders: a systematic review
Rucker, J., Jelen, L. A., Flynn, S. K., Frowde, K., & Young, A. H. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116679368 · Cited by 197
Gouzoulis-Mayfrank, E., Heekeren, K., Neukirch, A., Stoll, M., Stock, C., Obradovic, M., & Kovar, K. (2005) · Pharmacopsychiatry · doi:10.1055/s-2005-916185 · Cited by 194
Hermle, L., Fünfgeld, M., Oepen, G., Botsch, H., Borchardt, D., Gouzoulis, E., Fehrenbach, R. A., & Spitzer, M. (1992) · Biological Psychiatry · doi:10.1016/0006-3223(92)90059-9 · Cited by 183
Detecting Bipolar Depression From Geographic Location Data
Palmius, N., Tsanas, A., Saunders, K. E. A., Bilderbeck, A. C., Geddes, J. R., Goodwin, G. M., & De Vos, M. (2017) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2016.2611862 · Cited by 180
Self-citationLSD enhances the emotional response to music
Kaelen, M., Barrett, F. S., Roseman, L., Lorenz, R., Family, N., Bolstridge, M., Curran, H. V., Feilding, A., Nutt, D., & Carhart-Harris, R. L. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4014-y · Cited by 179
Self-citationValle, M., Maqueda, A. E., Rabella, M., Rodríguez-Pujadas, A., Antonijoan, R. M., Romero, S., Alonso, J. F., Mañanas, M. À., Barker, S., Friedlander, P., et al. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.03.012 · Cited by 173
Bonson, K. R. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00145-4 · Cited by 159
Richards, W. A. (2015) · Columbia University Press eBooks · doi:10.7312/columbia/9780231174060.001.0001 · Cited by 149
Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans
Carter, O. L., Hasler, F., Pettigrew, J. D., Wallis, G. M., Liu, G. B., & Vollenweider, F. X. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0930-9 · Cited by 146
Kohn, B., & Hofmann, A. (1981) · The Antioch Review · doi:10.2307/4638477 · Cited by 146
Discontinuation symptoms in depression and anxiety disorders
Baldwin, D. S., Montgomery, S. A., Nil, R., & Lader, M. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705006358 · Cited by 140
Riba, J., Anderer, P., Jané, F., Saletu, B., & Barbanoj, M. J. (2004) · Neuropsychobiology · doi:10.1159/000077946 · Cited by 134
Schünemann, H. J., Fretheim, A., & Oxman, A. D. (2006) · Health Research Policy and Systems · doi:10.1186/1478-4505-4-21 · Cited by 132
Baker‐Glenn, E. A., Park, B., Granger, L., Symonds, P., & Mitchell, A. J. (2011) · Psycho-Oncology · doi:10.1002/pon.1759 · Cited by 130 · cited 1×
“But, they are often not very severe and in fact patients may choose not to seek help in their treatment (Baker-Glenn et al, 2011).”
Background(2013) · Choice Reviews Online · doi:10.5860/choice.50-5307 · Cited by 118
Treatment of alcoholism using psychedelic drugs: a review of the program of research.
Mangini, M. (1998) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1998.10399714 · Cited by 114
L.S.D. 25 as an aid in psychotherapy; preliminary report of a new drug.
Busch, A., & Johnson, W. (1950) · PubMed · Cited by 114
Sacred Knowledge: Psychedelics and Religious Experiences
Richards, W. A. (2015) · doi:10.7312/rich17406 · Cited by 114
Carhart-Harris, R. L., & Nutt, D. (2010) · Journal of Substance Use · doi:10.3109/14659890903271624 · Cited by 106
Self-citationDrugs and Mysticism: The Bwiti Cult of the Fang
Binet, J. (1974) · Diogenes · doi:10.1177/039219217402208603 · Cited by 97
Jokela, M. M., Keltikangas‐Järvinen, L., Mika Kivimaki, B., Puttonen, S., Elovainio, M. J., Rontu, R., & Lehtimäki, T. J. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.356 · Cited by 95
Efficacy and Enlightenment: LSD Psychotherapy and the Drug Amendments of 1962
Oram, M. (2014) · Journal of the history of medicine and allied sciences · doi:10.1093/jhmas/jrs050 · Cited by 93
The Differential Susceptibility Hypothesis
Belsky, J. (2016) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2015.4263 · Cited by 92
Bonson, K. R., & Murphy, D. L. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00102-7 · Cited by 76
Muguruza, C., Miranda-Azpiazu, P., Dı́ez-Alarcia, R., Morentín, B., González‐Maeso, J., Callado, L. F., & Meana, J. J. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.08.009 · Cited by 69
Identifying Difficult-to-Treat Depression
Gaynes, B. N. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.8133su1c.02 · Cited by 64
Neuronal correlates of visual and auditory alertness in the DMT and ketamine model of psychosis
Daumann, J., Wagner, D. R., Heekeren, K., Neukirch, A., Thiel, C. M., & Gouzoulis‐Mayfrank, E. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109103227 · Cited by 62
Experienced Drug Users Assess the Relative Harms and Benefits of Drugs: A Web-Based Survey
Carhart-Harris, R. L., & Nutt, D. (2013) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2013.825034 · Cited by 54
Self-citationThe Use of LSD in Psychotherapy
Grof, S. (1970) · Journal of Psychedelic Drugs · doi:10.1080/02791072.1970.10471362 · Cited by 37
MOKSHA - Writings on Psychedelics and the Visionary Experience 1931 - 1963
Huxley, A., Horowitz, M., & Palmer, C. L. (1983) · Medical Entomology and Zoology · Cited by 34
Albion Dreaming: A popular history of LSD in Britain
Roberts, A. (2008) · Cited by 34
THE PSYCHOTOMIMETIC DRUGS. AN OVERVIEW.
Cole, J. O., & Katz, M. M. (1964) · PubMed · Cited by 31
Fiocco, A. J. (2007) · Frontiers in Behavioral Neuroscience · doi:10.3389/neuro.08.003.2007 · Cited by 28
Dressler, W. W., Balieiro, M. C., de Araújo, L. F., Silva, W. A., & dos Santos, J. E. (2016) · Social Science & Medicine · doi:10.1016/j.socscimed.2016.05.033 · Cited by 25
On some effects of lysergic acid diethylamide (L.S.D. 25) in normal volunteers.
Bradley, P. B., Elkes, C., & Elkes, J. (1953) · PubMed · Cited by 17
Moksha: Writings on Psychedelics and the Visionary Experience
Krippner, S. (1982) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1982.10471941 · Cited by 5
Research works printed but not linked: 6
- Huxley A (1954) The Doors of Perception. On the author's sensations under the influence of the drug mescalin.. Chatto & Windus: London.
- Pahnke WN (1966). Drugs and mysticism. Int J Parapsychol 8: 295–315.
- Passie T (1996). Hanscarl leuner—pioneer of hallucinogen research and psycholytic therapy. Maps Newslett 7: 46–49.
- Stoll W (1947). Lysergsäure-diäthyl-amid, ein Phantastikum aus der Mutterkorngruppe. Schweiz Arch Neur 60: 1–2.
- Wasson RG (1957). Seeking the magic mushroom. LIFE Magazine 49: 100–102.
- Watts R, Day C, Krzanowski J, Nutt D, Carhart-Harris R (2017). Patients' accounts of increased 'connection' and 'acceptance' after psilocybin for treatment-resistant depression. J Hum Psychol (in press).
Cited by
Sorted by citations
Trial of Psilocybin versus Escitalopram for Depression
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032994 · Cited by 1,391
Self-citationPsychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics
Carhart-Harris, R. L., & Friston, K. J. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017160 · Cited by 1,180
“There is growing interest in the potential of psychedelics to treat various psychiatric disorders (Carhart-Harris and Goodwin, 2017; Rucker et al., 2018).”
BackgroundPsilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970
“See Carhart-Harris and Goodwin (2017) for a review of historical and recent trials with psychedelics.”
BackgroundInfluentialSelf-citationRoseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808
“Given the growing evidence favoring the therapeutic value of psychedelics (dos Santos et al., 2016; Rucker et al., 2016; Carhart-Harris and Goodwin, 2017), it is timely that we better understand their therapeutic mechanisms.”
BackgroundSelf-citation
Metadata
- Authors
- Carhart-Harris, R. L., & Goodwin, G. M.
- Affiliations
- Imperial College London (GB)
- Oxford Health NHS Foundation Trust (GB)
- Corresponding author
- Carhart-Harris, Robin L
- Venue
- Neuropsychopharmacology
- Published
- 2017-04-26
- Volume
- 42
- Issue
- 11
- Pages
- 2105-2113
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- PMC
- PMC5603818
- OpenAlex
- W2610144880
- Cited by
- 706
- References
- 86
- Citations by year
- 2026: 107 · 2025: 129 · 2024: 96 · 2023: 81 · 2022: 76 · 2021: 59 · 2020: 75 · 2019: 30 · 2018: 38 · 2017: 12
- FWCI
- 6.41
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Strong
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- psychedelics, psilocybin, LSD, depression treatment, mood disorders, alcoholism, psychedelic drug regulation
- MeSH terms
- Animals, Mental Disorders, Hallucinogens, Humans, Psilocybin, History, 20th Century, History, 21st Century
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
